Dihexa: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข2 clinical studies cited
- โขOverall evidence level: low
- โข5 research gaps identified
Research Studies
Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents
McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW (2013) โข Journal of Pharmacology and Experimental Therapeutics
Foundational study characterizing dihexa as a metabolically stable, orally active, BBB-permeant angiotensin IV analog. Demonstrated cognitive enhancement in aged rats and scopolamine-treated rats.
Key Findings
- Oral dihexa (2 mg/kg/day) improved Morris water maze performance in 24-month-old rats
- Dihexa reversed scopolamine-induced cognitive deficits
- Compound demonstrated oral bioavailability and BBB permeability
- Induced spinogenesis and synaptogenesis at picomolar concentrations in vitro
Limitations: Animal study only; limited sample sizes; no long-term safety assessment; some authors later implicated in data integrity issues
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway
Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y (2021) โข Brain Sciences
Independent study demonstrating that dihexa rescues cognitive impairment in APP/PS1 Alzheimer's model mice through PI3K/AKT pathway activation, anti-inflammatory effects, and anti-apoptotic mechanisms.
Key Findings
- Dihexa restored spatial learning and memory in Morris water maze
- Increased neuronal cell density and SYP protein expression
- Reduced activation of astrocytes and microglia
- Decreased IL-1beta and TNF-alpha; increased IL-10
- Activated PI3K/AKT signaling pathway; wortmannin reversed effects
Limitations: Animal model only; APP/PS1 mice do not fully recapitulate human AD; no pharmacokinetic data reported; limited dose-response characterization
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 45+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขNo human clinical trials for safety, pharmacokinetics, or efficacy
- โขLong-term safety studies in any species, particularly regarding oncogenic potential via c-Met/HGF pathway activation
- โขIndependent replication of key mechanistic findings following the retraction of the Benoist et al. 2014 study
- โขDose-response characterization across multiple cognitive paradigms
- โขComprehensive pharmacokinetic profiling including half-life, distribution, and metabolism
Research Overview#
Dihexa (PNB-0408) has a limited preclinical evidence base consisting primarily of animal studies conducted at Washington State University and one independent study in China. No human clinical trials have been conducted. The evidence level is classified as low due to the exclusively preclinical nature of the data, small sample sizes, the retraction of a key mechanistic study, and the absence of independent replication for several core findings.
Key Preclinical Studies#
McCoy et al. (2013) -- Foundational Characterization#
McCoy et al. (PMID: 23055539) published the primary characterization of dihexa as a procognitive agent. This study evaluated a series of metabolically stabilized angiotensin IV analogs, identifying dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) as the lead compound based on its:
- Metabolic stability: Resistance to aminopeptidase and carboxypeptidase degradation
- BBB permeability: Brain concentrations achieved after systemic administration
- Oral bioavailability: Approximately 38% oral absorption
- In vivo efficacy: Significant improvement in Morris water maze performance in aged (24-month-old) Sprague-Dawley rats at 2 mg/kg/day oral dose
The study also demonstrated that dihexa reversed scopolamine-induced amnesia in younger rats, suggesting effects on cholinergic-dependent memory pathways. In vitro, dihexa induced spinogenesis and synaptogenesis at picomolar concentrations in hippocampal neurons.
Sun et al. (2021) -- APP/PS1 Alzheimer's Model#
This independent study (PMID: 34827486) from a Chinese research group tested dihexa in APP/PS1 double-transgenic mice, an established model of Alzheimer's disease featuring amyloid plaque deposition and cognitive deficits.
Key findings:
- Dihexa restored spatial learning and cognitive function in the Morris water maze
- Nissl staining showed increased neuronal cell density and synaptophysin (SYP) protein expression
- Glial activation was reduced, with decreased astrocyte and microglia activation markers
- Pro-inflammatory cytokines IL-1beta and TNF-alpha were significantly reduced, while anti-inflammatory IL-10 increased
- The PI3K/AKT signaling pathway was activated by dihexa, and the PI3K inhibitor wortmannin reversed both anti-inflammatory and anti-apoptotic effects
This study is important as it provides independent corroboration of dihexa's cognitive-enhancing effects and identifies a specific signaling mechanism (PI3K/AKT) distinct from but related to the HGF/c-Met pathway proposed in the Washington State University work.
Retracted Study#
Benoist et al. (2014) -- Retracted#
A 2014 study by Benoist, Kawas, Wright, Harding et al. in the Journal of Pharmacology and Experimental Therapeutics (originally PMID: 25187433) provided key mechanistic evidence that dihexa's procognitive and synaptogenic effects were dependent on HGF/c-Met system activation. This paper was retracted following a Washington State University investigation that found figures 1B, 2A/C, and associated data contained falsified and/or fabricated elements. Kawas and Harding were identified as solely responsible for the data integrity violations.
The retraction significantly weakens the mechanistic evidence base for dihexa, particularly the direct evidence linking its cognitive effects to HGF/c-Met activation. However, the 2013 McCoy study (which preceded the retracted work) and the 2021 Yun study (from an independent group) provide some supporting evidence through different experimental approaches.
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | Animal studies only | No randomized controlled human trials |
| Sample size | Small | Typical rodent study n-values |
| Consistency | Mixed | Independent replication exists but key study retracted |
| Independent replication | Partial | 2021 Chinese study partially confirms findings |
| Regulatory status | None | Not approved in any jurisdiction |
| Data integrity | Compromised | Key 2014 mechanistic study retracted |
| Long-term safety | Unknown | No long-term studies in any species |
Research Gaps#
-
No human data: Complete absence of human pharmacokinetic, safety, or efficacy data.
-
Oncogenic risk: The c-Met/HGF pathway plays a critical role in cancer biology. Sustained activation could theoretically promote tumor growth. No carcinogenicity studies have been conducted.
-
Mechanistic validation: Following the retraction of the Benoist 2014 study, independent confirmation of HGF/c-Met-dependent mechanism in cognitive models is needed.
-
Pharmacokinetic profiling: Published plasma half-life, tissue distribution, and metabolic pathway data are incomplete.
-
Dose-response studies: Limited dose-response characterization across different cognitive paradigms and species.
Related Reading#
Frequently Asked Questions About Dihexa
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.